<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672633</url>
  </required_header>
  <id_info>
    <org_study_id>08010028</org_study_id>
    <nct_id>NCT00672633</nct_id>
  </id_info>
  <brief_title>Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides</brief_title>
  <official_title>A Double Blind Randomized Controlled Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a randomized clinical trial to evaluate the efficacy of Lovaza
      (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old
      whose baseline triglycerides range from 150 mg/dl to 1000 mg/dl. Seventy subjects will be
      recruited at baseline and randomized to the treatment condition, Lovaza 4 grams/day for 6
      months or the control condition, a corn oil placebo, 4 tablets a day for 6 months.
      Participants in both the treatment and control groups will receive the standard of care,
      which is dietary advice to follow a low, refined carbohydrate and low saturated fat diet that
      emphasizes increasing intake of fruits and vegetables and eating 2 servings per week of
      fishes rich in omega-3 fatty acids, consistent with the American Heart Association
      recommendations. The primary outcome will be change in fasting triglycerides from baseline to
      3 months. The investigators hypothesize that patients who receive LOVAZA will have
      significantly greater reductions in plasma triglyceride levels when compared to patients on
      placebo at 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to conduct a placebo controlled, double blind, parallel group
      randomized trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing
      triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from150
      mg/dl to 1000 mg/dl. Seventy subjects will be recruited at baseline and randomized to the
      treatment condition, Lovaza 4 grams/day for 6 months or the control condition, a corn oil
      placebo, 4 tablets a day for 6 months. Participants in both the treatment and control groups
      will receive the standard of care, which is dietary advice to follow a low, refined
      carbohydrate and low saturated fat diet that emphasizes increasing intake of fruits and
      vegetables and eating 2 servings per week of fishes rich in omega-3 fatty acids, consistent
      with the American Heart Association recommendations (Kris-Etherton, 2003). Subjects will be
      randomized to the treatment or control condition after a 4 week run-in period of dietary
      education and advice. The primary outcome will be change in fasting triglycerides from
      baseline to 3 months.

      2.0 SPECIFIC AIMS

      2.1 Primary Aim/Outcome

        -  To determine the efficacy of LOVAZA in reducing plasma triglyceride levels among
           adolescents, ages 12-19 years with mild to moderate hypertriglyceridemia. We hypothesize
           that patients who receive LOVAZA will have significantly greater reductions in plasma
           triglyceride levels when compared to patients on placebo at 3 months.

      2.2 Secondary Aims/Outcome

        -  To determine whether the efficacy of LOVAZA varies with duration of treatment, 3 months
           versus 6 months.

        -  To determine the effects of LOVAZA on plasma HDL and LDL cholesterol at 3 months and 6
           months.

        -  To determine the effects of LOVAZA on systolic and diastolic blood pressure at 3 months
           and 6 months.

      2.3 Exploratory Aims

        -  To describe the effects of LOVAZA on vascular reactivity/endothelial function as
           measured by pulse amplitude at 3 months and 6 months.

        -  To describe the effects of LOVAZA on levels of biomarkers of inflammation as measured by
           C-Reactive Protein at 3 months and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very slow recruitment.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting Triglycerides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Low Density Lipoprotein Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>High Density Lipoprotein Cholesterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>A , Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza, 4 grams/day orally for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corn Oil Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn Oil Pill, 4 pills/day orally for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>Lovaza , 4 grams/day orally for 6 months</description>
    <arm_group_label>A , Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corn Oil Pill, 4 pills/day orally for 6 months</description>
    <arm_group_label>Corn Oil Pill</arm_group_label>
    <other_name>Corn Oil Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 10-19 years old

          -  Fasting Triglyceride levels of 150-1000 mg/dl at the screening and baseline visit

          -  Ability to swallow pills

          -  Informed consent from a parent or legal guardian of minors or adult subject

          -  Written assent from the adolescent to participate in the study

          -  English or Spanish speaking

        Exclusion Criteria:

          -  Food Allergy to Fish or any components of the pills which includes alpha tocopherol,
             partially hydrogenated vegetable oils including soybean oils and gelatin and glycerol
             or corn oil, and iron oxide or iron oxide containing food color additives.

          -  Pregnancy or positive urine pregnancy test for those females who have begun
             menstruating

          -  Breast feeding

          -  Alcohol Use: Patient is unable to abstain from alcohol use during the study. This will
             be assessed by asking the following questions: &quot;During the past 30 days, on how many
             days did you have at least one drink of alcohol?&quot;; &quot;During the past 30 days, on how
             many days did you have 5 or more drinks of alcohol in a row, that is, within a couple
             of hours?&quot;; &quot;This study requires that you abstain from alcohol use during the course
             of the study. Do you think you can do this?&quot;

          -  Known Bleeding Disorder or Coagulopathy or treatment with anticoagulant medications or
             low platelet counts, abnormal PT, or PTT.

          -  Significant cognitive or psychosocial disorder or medical illness that would limit
             participation in the trial.

          -  Type 1 or 2 Diabetes or fasting glucose that is &gt;=126 mg/dl

          -  Liver disease or an ALT greater than 2 times upper limit of normal

          -  Treatment with medications that affect triglyceride levels, including oral
             hypoglycemic agents or insulin.

          -  Be currently taking the same oral contraceptive pills for less than the past three
             months or intend to change or discontinue prescription oral contraceptive pills used
             in the next seven months

          -  Be currently taking any over-the-counter supplements that affect triglycerides or
             lipid metabolism including over the counter fish oil supplements.

          -  Treatment for or diagnosis of a thyroid disorder or an elevated TSH level at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavroula K Osganian, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara DeFerranti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>March 8, 2013</results_first_submitted>
  <results_first_submitted_qc>May 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <last_update_submitted>May 24, 2013</last_update_submitted>
  <last_update_submitted_qc>May 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Voula Osganian</investigator_full_name>
    <investigator_title>Physician Scientist</investigator_title>
  </responsible_party>
  <keyword>Omega 3 Fatty Acids</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Lovaza</keyword>
  <keyword>Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recuited from medical clinics at Boston Children's Hospital and referrals from community pediatricians. Recruitment took place from July 2008 to October 2011.</recruitment_details>
      <pre_assignment_details>Eligible patients participated in a 4 week dietary counseling run-in period before randomization. Patients were randomized if their triglycerides remained at or above 150 mg/dl after the 4 week run in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lovaza</title>
          <description>Treatment Arm: 4 grams/day orally for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Corn oil placebo: 4 pills/day orally for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lovaza</title>
          <description>Treatment Arm</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Corn oil placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="2.4"/>
                    <measurement group_id="B2" value="14.7" spread="2.7"/>
                    <measurement group_id="B3" value="14.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Fasting Triglycerides</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230" spread="44"/>
                    <measurement group_id="B2" value="225" spread="55"/>
                    <measurement group_id="B3" value="227" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fasting Triglycerides</title>
        <description>Fasting Triglycerides</description>
        <time_frame>3 months</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Treatment Arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Triglycerides</title>
          <description>Fasting Triglycerides</description>
          <population>Intention to Treat</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" spread="18"/>
                    <measurement group_id="O2" value="186" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed with 80% power to detect a net improvement of Triglyceride elevles with a sample size of 60.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>20</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol</title>
        <description>Low Density Lipoprotein Cholesterol</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Treatment Arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Cholesterol</title>
          <description>Low Density Lipoprotein Cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" spread="11"/>
                    <measurement group_id="O2" value="104" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No power calculations done for this outcomes</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated Measures</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>16</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL Cholesterol</title>
        <description>High Density Lipoprotein Cholesterol</description>
        <time_frame>3 months</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza</title>
            <description>Treatment Arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Corn oil placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HDL Cholesterol</title>
          <description>High Density Lipoprotein Cholesterol</description>
          <population>Intention to Treat</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="1.7"/>
                    <measurement group_id="O2" value="33.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No power calculations were conducted for this outcome</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated Measures</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lovaza</title>
          <description>Treatment Arm</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Corn oil placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Stavroula Osganian, Principal Investigator</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>8572184728</phone>
      <email>stavroula.osganian@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

